Havrix (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix is indicated for the active immunization against hepatitis A virus infection in several clinical situations.

• Primary prevention of hepatitis A infection in healthy individuals.
• Pre‑travel protection for persons traveling to regions where hepatitis A is endemic.
• Outbreak control when hepatitis A cases are identified in a community.
• Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A and are not previously immunized.
• Immunization of children and adolescents as part of routine vaccination programs.

The safety profile of Havrix includes both common, mild reactions and rare, more serious events.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or mild malaise.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face.
• Guillain‑Barré syndrome, a rare neurological disorder.
• Persistent high fever or severe rash.

Before administering Havrix, health professionals should consider several precautionary factors to ensure safe use.

• Confirm that the individual has not previously received a hepatitis A vaccine or has documented immunity.
• Defer vaccination in persons with a known severe allergy to any vaccine component, including algeldrate.
• Use caution in individuals with a history of hypersensitivity reactions to previous doses of Havrix.
• Assess the benefit‑risk balance for pregnant or breastfeeding women, as safety data are limited.
• Monitor for signs of an allergic reaction for at least 15 minutes after injection.
• Consider postponing vaccination in patients with acute moderate or severe illness.
• Review immunocompromised status, as response to the vaccine may be reduced.

Havrix generally has a low potential for drug interactions, but certain substances may affect its safety or effectiveness.

Avoid

• Concurrent administration of other vaccines containing live attenuated viruses, which may interfere with immune response.
• Use of immunoglobulin products or blood products containing anti‑hepatitis A antibodies within two weeks before or after vaccination.

Use with caution

• Immunosuppressive therapies (e.g., corticosteroids, chemotherapy) that may diminish antibody production.
• Antipyretic or analgesic medications taken prophylactically, which could mask mild post‑vaccination symptoms.
• Chronic liver disease medications, where hepatitis A infection risk is higher and vaccination timing may need adjustment.